Sharon Klahre | Head, Investor Relations |
Michael Metzger | Chief Executive Officer |
Neil Gallagher | President and Head of R&D |
Keith Goldan | Chief Financial Officer |
Dr. Anjali Ganguli | Chief Business Officer |
Madhu Kumar | Goldman Sachs |
Eva Privitera | TD Cowen |
Anupam Rama | JPMorgan |
Yigal Nochomovitz | Citigroup |
Peter Lawson | Barclays |
Kalpit Patel | B. Riley Securities |
Joel Beatty | Baird |
Dara Azar | Stifel |
Justin Zelin | BTIG |
Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first quarter 2023 financial and operating results.